Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• "Moderate Buy" consensus from eight analysts (six buy, one hold, one sell) with an average 1-year target of $8.00.
• Analyst views are mixed — Morgan Stanley remains bullish with a $12 price target while Weiss Ratings and Wall Street Zen have issued sell ratings, and several brokers recently adjusted targets around $7–9.
• Sana is a clinical-stage biotech with a market cap of about $833M, negative earnings (last quarter EPS -$0.16; consensus -1.16 for the year), and high institutional ownership at 88.23%.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $8.00.

A number of brokerages recently commented on SANA. Weiss Ratings restated a "sell (e+)" rating on shares of Sana Biotechnology in a report on Monday, December 29th. HC Wainwright reduced their target price on shares of Sana Biotechnology from $9.00 to $7.00 and set a "buy" rating for the company in a research note on Wednesday, March 4th. Bank of America lifted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Tuesday, January 6th. Morgan Stanley restated an "overweight" rating and issued a $12.00 price target on shares of Sana Biotechnology in a report on Friday, March 13th. Finally, Wall Street Zen cut Sana Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday, February 7th.

Hedge Funds Weigh In On Sana Biotechnology

A number of large investors have recently bought and sold shares of the company. Rockefeller Capital Management L.P. lifted its position in shares of Sana Biotechnology by 74.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock worth $39,000 after purchasing an additional 4,088 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in Sana Biotechnology during the third quarter worth $37,000. LRI Investments LLC bought a new position in Sana Biotechnology in the fourth quarter valued at $41,000. Jacobi Capital Management LLC bought a new position in Sana Biotechnology in the fourth quarter valued at $41,000. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in Sana Biotechnology in the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Stock Performance

NASDAQ SANA opened at $3.12 on Tuesday. The business has a 50 day simple moving average of $4.01 and a 200 day simple moving average of $4.15. Sana Biotechnology has a 52-week low of $1.26 and a 52-week high of $6.55. The stock has a market cap of $832.63 million, a price-to-earnings ratio of -3.22 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.03). On average, analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.